Get started
Author

Lennie Sender

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
2022 · Karim Chamie, Sam S. Chang, et al. · NEJM Evidence · 181
T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.
1993 · K Weinberg, M S Hershfield, et al. · Journal of Clinical Investigation · 56
PDF
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge
2021 · Elizabeth Gabitzsch, Jeffrey T. Safrit, et al. · Frontiers in Immunology · 28
Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP Study
2020 · Elizabeth Gabitzsch, Jeffrey T. Safrit, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 18
PDF
Quality of Life in the Phase 2/3 Trial of N-803 Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin‒Unresponsive Nonmuscle-Invasive Bladder Cancer
2024 · Karim Chamie, Sam S. Chang, et al. · Urology Practice · 17
Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
2021 · Peter Sieling, Thomas King, et al. · medRxiv · 17
PDF
N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review
2024 · Karim Chamie, Sam S. Chang, et al. · Future Oncology · 13
PDF
Abstract P5-04-02: Safety and efficacy from first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK) in patients with 2nd-line or greater metastatic triple-negative breast cancer (TNBC)
2020 · Mira Kistler, Chaitali Nangia, et al. · Cancer Research · 8
Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate
2024 · Katayoun Moini, Tara Seery, et al. · The Oncologist · 7
Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+ Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous Dendritic Cells from Patients Previously Infected with SARS-CoV-2
2020 · Peter Sieling, Lise Zakin, et al. · medRxiv · 7
PDF
Prolonged Progression-Free Survival, Disease-Free Survival, and Cystectomy Avoidance With IL-15 Receptor Lymphocyte–Stimulating Agent NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Papillary-Only Nonmuscle-Invasive Bladder Cancer
2025 · Sam S. Chang, Karim Chamie, et al. · The Journal of Urology · 6
PDF
Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients
2025 · Tara Seery, Lennie Sender, et al. · Frontiers in Oncology · 6
PDF
Inclusion and Diversity in Oncofertility Care
2021 · Leslie Appiah, Antoinette Anazodo, et al. · Journal of Adolescent and Young Adult Oncology · 3
Abstract A018: Characterization of the anti-tumor efficacy of memory cytokine enriched NK cells against tumors with neuroendocrine features
2026 · Kristen Fousek, Lucas A. Horn, et al. · Cancer Immunology Research · 1
Ctim-23. First-in-human Immunotherapy Targeting Lymphopenia in Recurrent Glioblastoma Multiform (gbm): Nai and Pd-l1 T-hank Plus Bevacizumab With Complete Response
2025 · Simon Khagi, Jose Carrillo, et al. · Neuro-Oncology · 1
PDF
Pd12-12 an Update on Quilt-3.032: Complete Responses to N-803 Plus Bcg Therapy in Bcg-unresponsive Bladder Carcinoma in Situ (cis) With or Without Ta/t1 Papillary Disease
2025 · Sam S. Chang, Karim Chamie, et al. · The Journal of Urology · 1
Reply by Authors
2026 · Sam S. Chang, Karim Chamie, et al. · The Journal of Urology
Reply by Authors
2026 · Sam S. Chang, Karim Chamie, et al. · The Journal of Urology
Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ ± Papillary Disease
2026 · Sam S. Chang, Karim Chamie, et al. · The Journal of Urology
Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).
2026 · Simon Khagi, Jose Arganda Carrillo, et al. · Journal of Clinical Oncology
PDF
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)
2026 · Ajay Bansal, Elena M. Stoffel, et al. · Frontiers in Immunology
PDF
647 Combination immunotherapy with pembrolizumab, lenvatinib, N-803 and dendritic cell vaccine targeting HER2 in patients with advanced or metastatic endometrial cancer
2024 · Hoyoung M Maeng, Jennifer L Marte, et al. · Regular and Young Investigator Award Abstracts
358 Characterization of the anti-tumor activity of memory cytokine enriched NK cells against tumors with neuroendocrine features
2023 · Kristen Fousek, Lucas A Horn, et al. · Regular and Young Investigator Award Abstracts
PDF
710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist)
2021 · Kristen Fousek, Lucas Horn, et al. · Regular and Young Investigator Award Abstracts
PDF
Works count: 24
Citation count: 369
H-index: 8
I10-index: 7
Year
Topic
Type